Drug Trial Radar · NCT06692738
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,160
Planned (sponsor's estimate)
Start
Nov 18, 2024
Primary completion
Jul 1, 2030
Study completion Jul 1, 2030
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).
Conditions
- Non-small Cell Lung Cancer
Interventions
RilvegostomigDrug
Administered intravenously (IV) on Day 1 of each 21-day cycle
PembrolizumabDrug
Administered intravenously (IV) on Day 1 of each 21-day cycle
CarboplatinDrug
Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
PaclitaxelDrug
Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
Nab-paclitaxelDrug
Administered intravenously (IV) on Days 1, 8, and 15 of each 21-day cycle up to 4 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: Up to approximately 6 years
- Progression-free survival (PFS)Time frame: Up to approximately 6 years
Locations
333 sites in 26 countries. Site status is shown where the registry gives one.
Research Site
Tucson, Arizona · Recruiting
Research Site
Springdale, Arkansas · Recruiting
Research Site
Anaheim, California · Recruiting
Research Site
Beverly Hills, California · Recruiting
Research Site
Loma Linda, California · Recruiting
Research Site
Los Alamitos, California · Recruiting
Research Site
Redlands, California · Recruiting
Research Site
San Francisco, California · Recruiting
Research Site
Walnut Creek, California · Recruiting
Research Site
West Haven, Connecticut · Recruiting
Research Site
Newark, Delaware · Recruiting
Research Site
Bay Pines, Florida · Recruiting
Research Site
Fort Lauderdale, Florida · Recruiting
Research Site
Gainesville, Florida · Recruiting
Research Site
Gainesville, Florida · Withdrawn
Research Site
Jacksonville, Florida · Recruiting
Research Site
Athens, Georgia · Recruiting
Research Site
Atlanta, Georgia · Withdrawn
Research Site
Savannah, Georgia · Not yet recruiting
Research Site
Boise, Idaho · Recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Decatur, Illinois · Recruiting
Research Site
Hinsdale, Illinois · Recruiting
Research Site
Quincy, Illinois · Recruiting
Research Site
Rockford, Illinois · Withdrawn
Research Site
Fort Wayne, Indiana · Not yet recruiting
Research Site
Waterloo, Iowa · Recruiting
Research Site
Lexington, Kentucky · Recruiting
Research Site
Lexington, Kentucky · Withdrawn
Research Site
Louisville, Kentucky · Recruiting
Research Site
Louisville, Kentucky · Recruiting
Research Site
Alexandria, Louisiana · Withdrawn
Research Site
Baton Rouge, Louisiana · Recruiting
Research Site
Covington, Louisiana · Withdrawn
Research Site
Shreveport, Louisiana · Recruiting
Research Site
Shreveport, Louisiana · Recruiting
Research Site
Scarborough, Maine · Recruiting
Research Site
Baltimore, Maryland · Completed
Research Site
Bethesda, Maryland · Recruiting
Research Site
Bethesda, Maryland · Not yet recruiting
Showing 40 of 333 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.